Tumor Vaccines for Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

340 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-31

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glioma is the most common primary malignant intracranial tumor, characterized by limited clinical treatment options and extremely poor prognosis. There is an urgent need for the development of new technologies and clinical practice. With the advancement of immunotherapy, tumor therapeutic vaccines have emerged as a hot topic in the field of solid tumor immunotherapy. Several clinical trials have confirmed that tumor vaccines can improve the prognosis of glioma patients. Vaccines are the first systemic treatment technology in nearly 30 years that can simultaneously extend the overall survival of patients with newly diagnosed glioblastoma and recurrent glioblastoma in Phase III clinical trials. This novel approach holds significant clinical value and brings hope to large number of patients. Our team has previously developed a dendritic cell (DC) vaccine for glioma, and the phase II clinical trial has demonstrated that it can extend the prognosis of glioma patients. However, several patients benefit less from vaccine therapy. Therefore, the identification of molecular mechanisms that render patients unresponsive to vaccine treatment is critical to improving vaccine efficacy. This project aims to collect various types of clinical samples from patients, including glioma patients receiving tumor vaccine treatment, glioma patients receiving conventional clinical treatment without tumor vaccine, and non-tumor patients (hemorrhagic stroke, ischemic stroke, and traumatic brain injury). High-throughput sequencing techniques will be used to establish an immune microenvironment database, followed by bioinformatics analysis and molecular biology experiments to uncover the molecular mechanisms influencing vaccine efficacy. Artificial intelligence and deep learning technologies will be employed to extract molecular mechanisms related information from radiology images and pathology images. Ultimately, the project seeks to establish an integrated diagnostic and treatment model that combines imaging, pathology, and omics data to advance the clinical application of vaccines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of B7-H4 in Tumor Vaccine

NCT06156150

Glioma

RECRUITING

Study of DC Vaccination Against Glioblastoma

NCT01567202

Glioma Glioblastoma Multiforme Neoplasms

UNKNOWN PHASE2

MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

NCT06043232

Glioma

RECRUITING

Vaccine Therapy in Treating Patients With Malignant Glioma

NCT00612001

Brain and Central Nervous System Tumors

COMPLETED PHASE1

Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

NCT04888611

Recurrent Glioblastoma

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

glioma patients receiving tumor vaccine

tumor vaccine

Intervention Type BIOLOGICAL

tumor vaccine produced by our team

Radiotherapy

Intervention Type RADIATION

conventional treatment in clincial

Chemotherapy

Intervention Type DRUG

conventional treatment in clinical

Surgery

Intervention Type PROCEDURE

conventional treatment in clinical

glioma patients receiving conventional treatment

Radiotherapy

Intervention Type RADIATION

conventional treatment in clincial

Chemotherapy

Intervention Type DRUG

conventional treatment in clinical

Surgery

Intervention Type PROCEDURE

conventional treatment in clinical

non-tumor patients

Surgery

Intervention Type PROCEDURE

conventional treatment in clinical

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tumor vaccine

tumor vaccine produced by our team

Intervention Type BIOLOGICAL

Radiotherapy

conventional treatment in clincial

Intervention Type RADIATION

Chemotherapy

conventional treatment in clinical

Intervention Type DRUG

Surgery

conventional treatment in clinical

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The patients with glioma patients/non-tumor patients (hemorrhagic stroke, ischemic stroke, and traumatic brain injury) in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled:

1. They were no age limit, male and female;
2. The pathological results of frozen section during operation were gliomas or non-tumor;
3. Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis;
4. Sign informed consent.